The top analyst upgrades, downgrades and other research calls from Tuesday include Cheniere Energy, Consolidated Edison, Foot Locker, Shopify, Tesla, Veeco Instruments and Zoetis.
The top analyst upgrades, downgrades and other research calls on Tuesday include Ambarella, BlackBerry, Schlumberger, Valero Energy, Whiting Petroleum and Zynga.
With interest rates once again dropping as the geopolitical worries ratchet up, investors are concerned about owning good stocks and receiving dependable dividends. One place that looks very good now is pharmaceuticals.
These four new additions to Stifel's Select List are all rated Buy and make good sense for growth investors looking for new ideas.
Thursday’s top analyst upgrades, downgrades and initiations include Advanced Micro Devices, Comerica, General Mills, Mastercard and Vertex Pharmaceuticals.
Building on a turn toward more equity investments in the second quarter of this year, the top 50 hedge funds boosted their equity positions by nearly 3% in the third quarter.
Now is a good time to add quality stocks in front of what is usually a very good time of the year for equities. These four stocks offer investors solid upside potential.
A new Jefferies research report features top pharmaceutical picks for the fourth quarter. Any of these top picks make good sense for long-term growth and income portfolios.
A recent Merrill Lynch research report features the firm's top ideas for the fourth quarter. These eight stocks look like outstanding picks for growth stock accounts.
If there is one trend that has worked in America, it is the trend of betting on the public taking care of their pets. Now Merrill Lynch has issued a report on…
Despite recent market headwinds and volatility, there are strong underlying fundamentals among the large cap pharmaceuticals that are continuing to drive them forward.
A new Jefferies research report features the firm's top pharmaceutical stock picks in order of preference, and AbbVie stays in the top position.
Credit Suisse made a point to highlight a few animal health companies that stand to outperform the markets in 2016 and even beyond.
Jefferies has updated the thesis behind its "Top 5 for 2015" pharmaceutical stock picks
Some investors may raise an eye as Merrill Lynch adds Facebook at prices near a 52-week high. The bottom line is the company is basically in a world with no competition.
